Glenmark Pharmaceuticals Europe Ltd. (Glenmark) announced that it has launched a generic version of Seretide Accuhaler in Denmark. This is Glenmark’s first inhaled respiratory product launch in Europe.

Glenmark is the first generic company to receive regulatory approval for substitution in Denmark for its generic of Seretide Accuhaler.

Glenmark had entered into a strategic development & licensing agreement with Celon Pharma S.A. (Celon) to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone/Salmeterol dry powder inhaler in 15 European countries. Fluticasone/Salmeterol dry powder inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Glenmark has already received National Marketing Authorizations for the product in Sweden, Finland, Norway and Iceland.

“Denmark is the first country in Europe where Glenmark has launched its generic Fluticasone/Salmeterol dry powder inhaler (DPI) and we plan to commercialize this product across the Nordics in the near future. The grant of substitution in Denmark for this complex product affirms Glenmark’s capabilities in the respiratory segment,” said Achin Gupta, executive vice president & business head of Europe and Latin America, Glenmark Pharmaceuticals Ltd.

According to IQVIA data, Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of USD 864 million in Europe in the 12 month period ending September 2017.

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of oncology, respiratory disease, and dermatology.

Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs.